Form 4: Emergent BioSolutions CEO Joseph Papa Acquires Stock Options and Performance Stock Units

Emergent BioSolutions CEO Joseph Papa acquired 282,500 performance stock units and stock options on March 6, 2025, according to a recent SEC filing.

Summary

• On March 6, 2025, Joseph C. Papa, the President and CEO of Emergent BioSolutions Inc., acquired 282,500 performance stock units and 282,500 employee stock options.
• The performance stock units vest in three annual installments beginning on the day prior to the anniversary of the grant date, contingent upon continued service and achievement of Adjusted EBITDA targets for the 2025 fiscal year.
• Each performance stock unit represents the right to receive one share of common stock.
• The employee stock options, with an exercise price of $5.8, also vest in three equal installments beginning on the day prior to the anniversary date of the grant and expire on March 5, 2032.
• Following these transactions, Papa directly owns 282,500 shares of common stock and 1,032,500 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating alignment of management interests with company performance. The sentiment is neutral to positive as it suggests confidence in future performance.

Positives

• The acquisition of performance stock units aligns the CEO's interests with the company's performance, specifically Adjusted EBITDA for the 2025 fiscal year.
• The vesting schedule of both the performance stock units and employee stock options incentivizes continued service with the company.

Future Outlook

The vesting of the performance stock units is contingent upon the achievement of Adjusted EBITDA targets for the 2025 fiscal year, indicating a focus on financial performance.

Industry Context

Stock option and performance unit grants are a common practice in the biopharmaceutical industry to incentivize executives and align their interests with those of shareholders. The specific terms of the grants, such as the vesting schedule and performance metrics, are tailored to the company's specific goals and circumstances.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biopharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options and performance-based equity awards to incentivize their executives.
• The vesting schedules and performance metrics associated with these awards vary depending on the company's specific goals and circumstances.

Stakeholder Impact

• The acquisition of performance stock units and stock options by the CEO aligns his interests with those of shareholders, potentially leading to increased shareholder value.
• The vesting requirements based on continued service incentivize the CEO to remain with the company, providing stability.

Key Dates